COVID-19 Update: We are currently shipping orders daily. However, due to transit disruptions in some geographies, deliveries may be delayed. To provide all customers with timely access to content, we are offering 50% off Science and Technology Print & eBook bundle options. Terms & conditions.
Autophagy and Senescence in Cancer Therapy - 1st Edition - ISBN: 9780128241585

Autophagy and Senescence in Cancer Therapy, Volume 150

1st Edition

Serial Volume Editors: Paul Fisher David Gewirtz
Hardcover ISBN: 9780128241585
Imprint: Academic Press
Published Date: 1st April 2021
Page Count: 312
Sales tax will be calculated at check-out Price includes VAT/GST

Institutional Subscription

Secure Checkout

Personal information is secured with SSL technology.

Free Shipping

Free global shipping
No minimum order.

Table of Contents

1. Autophagy and senescence, converging roles in pathophysiology
Andrew Young
2. Cellular senescence and tumor promotion: role of the Unfolded Protein Response
Olivier Pluquet
3. Autophagy and Senescence in Cancer Stem Cells
Paul Fisher
4. Targeting the Stress Support Network Regulated by Autophagy and Senescence for Cancer Treatment
Chanhee Kang
5. Autophagy and PTEN in DNA damage-induced senescence
Alexandru Almasan
6. mTOR as a senescence manipulation target: A forked road
Francis Rodier and Apostolos Christopoulos
7. The role of autophagy in escaping therapy-induced senescence
Ewa Sikora
8. The contribution of autophagy to the reversibility of therapy-induced senescence
David Gewirtz


Description

Advances in Cancer Research, Volume 150, the latest release in this ongoing series, covers the relationship(s) between autophagy and senescence, how they are defined, and the influence of these cellular responses on tumor dormancy and disease recurrence. Specific sections in this new release include Autophagy and senescence, converging roles in pathophysiology, Cellular senescence and tumor promotion: role of the unfolded protein response, autophagy and senescence in cancer stem cells, Targeting the stress support network regulated by autophagy and senescence for cancer treatment, Autophagy and PTEN in DNA damage-induced senescence, mTOR as a senescence manipulation target: A forked road, and more.

Key Features

  • Addresses the relationship between autophagy and senescence in cancer therapy
  • Covers autophagy and senescence in tumor dormancy
  • Explores autophagy and senescence in disease recurrence

Readership

Scientists and physician-scientists who are interested in how tumor cells respond to cancer therapeutics and potentially evade the cell killing effects of standard of care therapy


Details

No. of pages:
312
Language:
English
Copyright:
© Academic Press 2021
Published:
1st April 2021
Imprint:
Academic Press
Hardcover ISBN:
9780128241585

Ratings and Reviews


About the Serial Volume Editors

Paul Fisher

Paul Fisher

Paul B. Fisher, MPh, PhD, FNAI, Professor and Chairman, Department of Human and Molecular Genetics, Director, VCU Institute of Molecular Medicine Thelma Newmeyer Corman Chair in Cancer Research in the VCU Massey Cancer Center, VCU, School of Medicine, Richmond, VA, and Emeritus Professor, Columbia University, College of Physicians & Surgeons, New York, NY. Dr. Fisher is among the top 10% of NIH funded investigators over the past 35-years, published approximately 625 papers and reviews, and has 55 issued patents. He pioneered novel gene/discovery approaches (subtraction hybridization), developed innovative therapeutic approaches (Cancer Terminator Viruses), presented numerous named and distinguished lectures, founded several start-up companies, was Virginia Outstanding Scientist of 2014 and elected to the National Academy of Inventors in 2018. Dr. Fisher is a prominent nationally and internationally recognized cancer research scientist focusing on understanding the molecular and biochemical basis of cancer development and progression to metastasis and using this garnered information to develop innovative approaches for diagnosing and treating cancer. He discovered and patented novel genes and gene promoters relevant to cancer growth control, differentiation and apoptosis. His discoveries include the first cloning of p21 (CDK inhibitor), human polynucleotide phosphorylase, mda-9/syntenin (a pro-metastatic gene), mda-5 and mda-7/IL-24, which has shown promising clinical activity in Phase I/II clinical trials in patients with advanced cancers. Dr. Fisher alsohas a documented track record as a successful seasoned entrepreneur. He was Founder and Director of GenQuest Incorporated, a functional genomics company, which merged with Corixa Corporation in 1998, traded on NASDAQ and was acquired by GlaxoSmithKline in 2006. He discovered the cancer-specific PEG-Prom, which is the core technology of Cancer Targeting Systems (CTS, Inc.), a Virginia/Maryland-based company (at Johns Hopkins Medical Center) focusing on imaging and therapy (“theranostics”) of metastatic cancer (2014) by Drs. Fisher and Martin G. Pomper. He co-founded InVaMet Therapeutics (IVMT) and InterLeukin Combinatorial Therapies (ILCT) with Dr. Webster K. Cavenee (UCSD) (2017/2018).

Affiliations and Expertise

Institute of Molecular Medicine, Virginia Commonwealth University, VA, USA

David Gewirtz

David Gewirtz

Dr. Gewirtz received his PhD degree from Mt. Sinai School of Medicine of the City University of New York. He has been at Virginia Commonwealth University in the Department of Pharmacology and Toxicology and as a member of the Massey Cancer Center for his entire career. His work has been in the areas of cancer chemotherapy and radiotherapy, originally in breast cancer, but more recently extending to lung cancer, prostate cancer and head and neck cancer. His interests have long been in the nature of alternative tumor responses to therapy, most prominently autophagy and senescence. He has long argued that senescence is not an irreversible form of growth arrest, that senescence could represent one form of tumor dormancy and furthermore that recovery from senescence could contribute to disease recurrence. His most recent publication describes the impact of the senolytic agent, ABT-263 (navitoclax) on breast and lung tumor cells induced into senescence by cancer chemotherapy and radiation.

Affiliations and Expertise

Department of Pharmacology and Toxicology, Virginia Commonwealth University; Member of the Massey Cancer Center, VA, USA